for the process of manufacturing Vimovo. This will mean that if a competitor wants to come up with a generic version they will have to find a process that is significantly different, but has the same result. This is not easily done and costs a lot of money. This should protect POZN for a while after 2022.
V has been put on CVS caremark and Express Scripts exclusionary lists, therefore, sales will be tepid ( CVS and Express scripts fill 50% of all prescriptions in the US). One thing for sure POZN is guaranteed the royalty payment. December FDA decision is the catalyst for POZN sp going forward.